Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Key Discovery in Neurodegenerative Diseases
Uncategorized

Key Discovery in Neurodegenerative Diseases

By medwebOct 1, 2002
Share
Facebook Twitter Email

October 1, 2002

Contact: Megan Fellman at (847) 491-3115 or at
fellman@northwestern.edu

Key Discovery in Neurodegenerative Diseases

EVANSTON, ILL.— Northwestern University scientists have made a key molecular discovery that has implications for a wide range of diseases characterized by the loss of nerve function, including Huntington’s, Parkinson’s, Alzheimer’s and Lou Gehrig’s diseases, cystic fibrosis, and Creutzfeldt-Jakob disease, the human form of mad cow disease.

The findings, which are published in the October 1 issue of Nature Cell Biology , could lead to an understanding of how to prevent these diseases and to the development of effective drugs.

All human neurodegenerative diseases have two things in common. First, misfolded and damaged proteins clump together to form toxic species that aggregate, destroy cell function and cause disease. Second, studies have shown that special protective proteins, called molecular chaperones, can suppress these toxic effects. This question remained: How do the chaperones and aggregates interact with each other?

A research team led by Richard I. Morimoto, PhD, John Evans Professor of Biology, now can answer that question. The researchers have become the first to view, in living cells and in real time, the interactions between the beneficial molecular chaperone Hsp70 and the damaging protein aggregate, shedding light on how the chaperone works to minimize aggregate growth.

“We now understand how the chaperone influences the aggregate’s toxic effect on the cell,” said Dr. Morimoto. “We observed that the chaperone is binding to and then coming off the aggregate all the time. This dynamic relationship is unusual because the aggregate, the result of a genetic mutation, brings healthy and otherwise normal proteins to aggregate irreversibly with them. But this clearly is not the case with the molecular chaperone.”

Instead, the molecular chaperone is allowed, for reasons not fully understood, to do its work preventing healthy proteins essential to cell function from being bound to the aggregate, a biochemical “black hole.” The chaperone is continually sampling the aggregate to see what’s there and to release any healthy proteins from the aggregate’s clutches. This could suppress the aggregate’s growth, prolonging the life of the cell and delaying the onset of disease.

“These observations provide the first visual study of this cell survival activity,” said Dr. Morimoto, whose team studied the chaperone Hsp70 (a heat shock protein) and polyglutamine aggregates, the type of protein aggregate responsible for Huntington’s disease. “The molecular chaperones are not like other proteins.”

In order to visualize the behavior of chaperones and aggregates in an animal, the researchers use human tissue culture cells and C. elegans , a transparent roundworm whose biochemical environment is similar to that of human beings and whose genome, or complete genetic sequence, is known.

Although the Northwestern researchers are studying Huntington’s disease, these experimental models can be used to study other neurodegenerative diseases because of the common molecular components.

“Rick Morimoto’s studies provide insights into the genetic factors that may modify the precise timing of disease in polyglutamine disorders,” said Marcy E. MacDonald, associate professor of neurology at Harvard Medical School. “Hsp70 is a protein that makes a difference in a model system that measures a property of polyglutamine known to be important to the human disorders. As a result, it is a rational target for further study and drug intervention. Because he is using genetic criteria to guide his studies, Rick’s data have important implications for attacking the disease in the human patient.”

Proteins, made up of different combinations of amino acids, are basic components of all living cells. To do its job properly, each protein first must fold itself into the proper shape. In this process, the protein receives its folding instructions from its amino acid sequence and is assisted by a class of proteins known as heat shock proteins or molecular chaperones that function to prevent misfolding, or, in the case of already misfolded proteins, to detect them and prevent their further accumulation.

In Huntington’s disease, for example, a mutated gene directs production of a protein with an increasing number of consecutive residues of the amino acid glutamine. When the number of residues expands past 40, the protein exhibits unusual biochemical properties, causing the protein to misfold. This results in a loss of function and protein aggregation — in other words, disease.

“How do we use this new information about molecular chaperones to our advantage, to protect individuals from the molecular damage of disease?” said Dr. Morimoto. “That is our next challenge.”

Related to this research, Dr. Morimoto reported in the August issue of Proceedings of the National Academy of Sciences that the appearance of aggregates and polyglutamine protein toxicity associated with Huntington’s disease in C. elegans can be suppressed by a genetic pathway that controls aging.

Other authors on the Nature Cell Biology paper are Soojin Kim (lead author), Ellen Nollen and Kazunori Kitagawa, from Northwestern University, and Vytautas Bindokas, from the University of Chicago.

The research was supported by the National Institutes of Health, Huntington Disease Society of America Coalition for the Cure, Hereditary Disease Foundation, and Netherlands Organization for Scientific Research.

Education
Share. Facebook Twitter Email

Related Posts

Mar 7, 2023

A Day in the Life: Evan Edwards

Mar 7, 2023

Changes in Medical School Leadership

Jan 26, 2023

2022 Year in Review

Dec 29, 2022

Comments are closed.

Latest News

Sex-Specific Mechanisms for Major Depressive Disorder Identified in Response to Dysregulated Stress Hormones

Mar 23, 2023

Pre-Surgery Immunotherapy May Increase Survival in Advanced Melanoma

Mar 23, 2023

Hormone Therapy Plus Current Treatments Improves Survival in Prostate Cancer

Mar 22, 2023

How ChatGPT Has, and Will Continue to, Transform Scientific Research

Mar 21, 2023

New Directions for HIV Treatment

Mar 21, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20230317_NM651
20230317_NM610
20230317_NM569
20230317_NM537
20230317_NM331
20230317_NM323
20230317_NM316
20230317_NM336
20230317_NM626
20230317_NM662
20230317_NM655
20230317_NM642

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.